Abstract
Overview
Introduction
Combined drug sales in the five major European markets represent the
second-biggest market globally after the US. Unlike the US, which is dominated
by a wide range of private payers, governments are the major payers in Europe.
The monopsonistic nature of these markets provides governments with
significant leverage and they use extensive P&R controls to contain spiralling
healthcare costs.
Scope
- Evaluation of the pressures facing the drugs industry and how these
pressures will impact P&R
- Overview of global P&R controls, examining which are important in the
European market both currently and in the future
- In-depth analysis of each of the five major European markets, examining
both the healthcare systems and the key P&R infrastructure
- Identification of trends and recommendations shaping the European P&R
environment
Highlights
Better dialogue between healthcare providers and drugs companies is vital;
however, healthcare provider devolution has led to fragmentation of the key
European markets, making it difficult to identify key P&R stakeholders
Many European governments profess to be willing to reward innovative drugs,
however this is largely a smokescreen as debt-ridden governmental payers
increasingly prioritize cost containment
European drug developers need to prioritize P&R as an important factor in drug
development, and focus on securing strong P&R justification before
green-lighting me-too drugs
Reasons to Purchase
- Gain a clear understanding of the healthcare market dynamics and P&R
environment within each of the five major European healthcare markets
- Review P&R trends in Europe, based on Datamonitor's analysis and primary
research conducted with key stakeholders in the industry
- Gain insight into how P&R fits into company strategy and understand how
specific P&R trends are shaping the European markets
View Cart
